November 18, 2026

Stepping up from ICS/LABA to FF/UMEC/VI in Patients with Uncontrolled Asthma: Outcomes from the 52-Week PERFORM Pragmatic Randomized Controlled Trial

Oppenheimer JJ, Penz E, Baptist AP et al.  Adv Ther. 2026 Nov 16. doi: 10.1007/s12325-026-03860-5.

Abstract

Introduction

Asthma remains uncontrolled in many patients receiving inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), suggesting that guideline-recommended escalation to triple therapy is often delayed. We report outcomes in patients with uncontrolled, infrequently exacerbating asthma (understudied in traditional randomized controlled trials) stepping up from ICS/LABA to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) from the PERFORM trial.

Methods

PERFORM, a randomized, open-label, active-controlled, pragmatic trial in symptomatic adults with uncontrolled, infrequently exacerbating asthma, evaluated the effectiveness and safety of FF/UMEC/VI versus usual care ICS/LABA.

Outcomes included trough forced expiratory volume in 1 s (FEV1), asthma control (Asthma Control Questionnaire [ACQ-5/-6/-7]), and achieving clinical remission at Week 52 for the step-up (participants treated with ICS/LABA pre-randomization) and overall population. Safety was assessed throughout the study.

Results

Graphical Abstract
Overall, 783 of 1236 participants in PERFORM received ICS/LABA pre-randomization, with 392 and 391 randomized to FF/UMEC/VI and ICS/LABA, respectively. Statistically significant improvements in trough FEV1 were observed for FF/UMEC/VI versus ICS/LABA at Week 24 and were durable to Week 52 (least squares means treatment difference in change from baseline [95% confidence interval (CI)]: 66 ml [29, 103] and 67 ml [28, 106] at Weeks 24 and 52). FF/UMEC/VI showed greater odds of achieving ≥ 0.5-point improvement from baseline in ACQ-7 total score at Week 24 and achieving clinical remission at Week 52 versus ICS/LABA (adjusted odds ratio [95% CI]: 1.54 [1.12, 2.12] and 2.78 [1.82, 4.24]; not multiplicity adjusted). Results (including the Week 52 safety profile) were similar to the overall PERFORM population.

Conclusion

Escalation to FF/UMEC/VI from ICS/LABA improved lung function, asthma control, and clinical remission, with no unexpected safety findings versus usual care ICS/LABA at Weeks 24 and 52, consistent with the overall PERFORM population. Initiation with FF/UMEC/VI may address the unmet need for optimized treatment in patients with uncontrolled, infrequently exacerbating asthma.

PDF

No comments:

Post a Comment